Back

Fangzhou revenue rises 22.2% to RMB1.8245 billion in first-half 2026

Verifying
  • Fangzhou reported higher revenue and expanded AI-enabled chronic disease services in first-half 2026.
  • Revenue reached RMB1.8245 billion, increasing 22.2% year-on-year during the period.
  • Fangzhou worked with more than 1,800 suppliers and 1,000 pharmaceutical companies.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.